Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
| Actual shortage: | 217 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ATOMOXETINE | 10MG | CAPSULE | Resolved | 2019-05-15 | 2019-05-25 | 84108 |
| APO-ATOMOXETINE | 40MG | CAPSULE | Resolved | 2019-05-15 | 2019-06-01 | 84112 |
| APO-ATOMOXETINE | 10MG | CAPSULE | Resolved | 2019-08-07 | 2019-09-23 | 91067 |
| APO-ATOMOXETINE | 40MG | CAPSULE | Resolved | 2017-03-10 | 2017-07-20 | 61 |
| APO-ATOMOXETINE | 60MG | CAPSULE | Resolved | 2017-03-10 | 2017-07-20 | 64 |
| APO-ATOMOXETINE | 18MG | CAPSULE | Resolved | 2017-03-17 | 2017-07-17 | 3160 |
| APO-ATOMOXETINE | 40MG | CAPSULE | Resolved | 2023-06-02 | 2023-07-07 | 193600 |
| APO-ATOMOXETINE | 100MG | CAPSULE | Resolved | 2024-05-24 | 2024-10-11 | 228792 |
| APO-ATOMOXETINE | 25MG | CAPSULE | Resolved | 2024-05-30 | 2024-10-04 | 229164 |
| APO-ATOMOXETINE | 40MG | CAPSULE | Resolved | 2024-05-30 | 2024-10-04 | 229167 |
| APO-ATOMOXETINE | 10MG | CAPSULE | Resolved | 2024-07-12 | 2024-09-27 | 232818 |
| APO-ATOMOXETINE | 40MG | CAPSULE | Resolved | 2024-08-01 | 2024-10-04 | 234317 |
| APO-ATOMOXETINE | 25MG | CAPSULE | Resolved | 2024-09-05 | 2024-10-04 | 236872 |
| APO-ATOMOXETINE | 25MG | CAPSULE | Resolved | 2024-11-07 | 2024-12-20 | 242211 |
| APO-ATORVASTATIN | 80MG | TABLET | Resolved | 2024-05-10 | 2024-05-24 | 227725 |
| APO-ATORVASTATIN | 40MG | TABLET | Resolved | 2024-05-31 | 2024-06-07 | 229401 |
| APO-ATORVASTATIN | 80MG | TABLET | Resolved | 2024-09-05 | 2024-11-01 | 236875 |
| APO-ATORVASTATIN | 10MG | TABLET | Resolved | 2024-12-12 | 2025-01-03 | 245505 |
| APO-ATORVASTATIN | 80MG | TABLET | Resolved | 2023-11-17 | 2023-12-01 | 210695 |
| APO-ATORVASTATIN | 80MG | TABLET | Resolved | 2023-11-24 | 2023-12-01 | 211493 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |